Objective: This study aimed to investigate the long-term neurological symptoms following Coronavirus disease 2019 (COVID-19) vaccination in Saudi Arabia.
Methods: A cross-sectional online survey was conducted from September to November 2023, collecting data from 847 participants who had received at least one dose of a COVID-19 vaccine.
Results: The results revealed that the commonly reported symptoms were difficulty concentrating (37.4%, n = 317), amnesia (32.8%, n = 278), and insomnia (29.2%, n = 247). Headaches (28.0%, n = 237) had a higher significant association among females (76.4%, p-value < 0.001) and younger age groups (18-30 years) (62.0%, p-value = 0.009). Moreover, dizziness (22.2%, n = 188), depression (21.1%, n = 179), and the least reported altered smell or taste (18.4%, n = 156). Symptoms typically appeared within a few days (43.3%) to 6 months (33.0%) post-vaccination.
Conclusion: This study highlighted the need for continued monitoring and support for individuals experiencing neurological symptoms following COVID-19 vaccination. The prevalence of symptoms underscores the potential long-term neurological impact of these vaccines. Further research is needed, but this study provided important insights into the safety profile.
Key words: Neurological symptoms, COVID-19, vaccines, infection, long-term
|
